Research Project
Grant-in-Aid for Young Scientists (B)
We demonstrated that plasma concentration of sorafenib was significantly higher in patients with renal cell carcinoma or hepatocellular carcinoma who developed grade 2 or higher hand-foot skin reaction as compared with those without the adverse event. Furthermore, the cumulative incidence of grade 3/4 adverse events was closely related with early drug exposure in lung cancer patients treated with erlotinib. These findings suggest that drug concentrations could be a useful predictor for avoiding adverse events induced by molecular targeted agents.
All 2013 2012 2011 Other
All Journal Article (5 results) (of which Peer Reviewed: 5 results) Presentation (14 results) Remarks (3 results)
Clinical Pharmacokinetics
Volume: 52 Issue: 7 Pages: 593-609
10.1007/s40262-013-0058-5
Drug Metabolism and Pharmacokinetics
Volume: 27 Issue: 6 Pages: 631-639
10.2133/dmpk.DMPK-12-RG-026
130004933515
Cancer Chemotherapy and Pharmacology
Volume: 70 Issue: 3 Pages: 399-405
10.1007/s00280-012-1929-4
Clin. Lung Cancer
Volume: 12(5) Issue: 5 Pages: 307-312
10.1016/j.cllc.2011.06.004
Volume: 68 Issue: 4 Pages: 1089-1092
10.1007/s00280-011-1691-z
http://www.kuhp.kyoto-u.ac.jp/~yakuzai/main.htm